

References

- 1- **Abbassi, V. (1998):** Growth and normal puberty. *Pediatrics*, 102(2):507–511.
- 2- **Adham, I.M. and AgoulNIK, A.I. (2004):** Insulin-like 3 signalling in testicular descent. *Int. J. Androl.*, 27:257–265.
- 3- **Adiyaman, P.; Ocal, G.; Berberoglu, M.; Aycan, Z.; Evliyaoglu, O. and Cetinkaya, E. (2004):** Plasma testosterone response at 1st and 4th day after short- and long-term hCG stimulation test. *Turk. J. Pediatr.* 46:309–314.
- 4- **Aksglaede, L.; Christiansen, P.; Sørensen, K.; Boas, M.; Linneberg, A.; Main, K.M.; Andersson, A.M.; Skakkebaek, N.E. and Juul, A. (2011):** Serum concentrations of Anti-Müllerian Hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism. *Acta. Paediatr.*, 100(6):839-845.
- 5- **Aksglaede, L.; Sørensen, K.; Boas, M.; Mouritsen, A.; Hagen, C. P.; Jensen, R. B.; Petersen, J. H., Linneberg, A., Andersson, A.M., Main, K. M., Skakkebaek, N. E. and Juul, A. (2010):** Changes in Anti-Müllerian Hormone (AMH) throughout the Life Span: A Population-Based Study of 1027 Healthy Males from Birth (Cord Blood) to the Age of 69 Years. *J Clin Endocrinol Metab.*, 95(12):5357-64.
- 6- **Allard, S.; Adin, P.; Gouedard, L.; di Clemente, N.; Josso, N.; Orgebin-Crist, M. C.; Picard, J. Y. and Xavier, F. (2000):** Molecular mechanisms of hormone-mediated Müllerian duct regression: involvement of β -catenin. *Development*, 127: 3349–3360.
- 7- **Al-Qahtani A. and Groome, N.P. (2006):** Anti-müllerian hormone: Cinderella finds new admirers. *J. Clin. Endocrinol. Metab.*, 91:3760-3762.
- 8- **Al-Qahtani, A.; Muttukrishna, S.; Appasamy, M.; Johns, J.; Cranfield, M.; Visser, J.A. et al., (2005):** Development of a sensitive enzyme immunoassay for anti-Müllerian hormone and the evaluation of potential clinical applications in males and females. *Clin. Endocrinol. (Oxf)*, 63: 267–73.

- 9- **Ambler, G.R. (2009):** Androgen therapy for delayed male puberty. *Curr. Opin. Endocrinol. Diabetes Obes.*, 16(3):232-9.
- 10- **Andersen, C.Y. and Byskov, A.G. (2006):** Estradiol and regulation of anti-Müllerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles' fluid. *J. Clin. Endocrinol. Metab.*, 91:4064–4069.
- 11- **Anderson, D.L.; Thompson, G.W. and Popovich, F. (1975):** Interrelationships of dental maturity, skeletal maturity, height and weight from age 4 to 14 years. *Growth*, 39:453-462.
- 12- **Anderson, S.E.; Dallal, G.E. and Must, A. (2003):** Relative weight and race influence average age at menarche: results from two nationally representative surveys of U.S. girls studied 25 years apart. *Pediatrics*, 111:844–850.
- 13- **Arango, N.A.; Lovell-Badge, R. and Behringer, R.R. (1999):** Targeted mutagenesis of the endogenous mouse MIS gene promoter in vivo definition of genetic pathways of vertebrate sexual development. *Cell*, 99:409–419.
- 14- **Baarends, W.M.; Uilenbroek, J.T.; Kramer, P.; Hoogerbrugge, J.W.; van Leeuwen, E.C.; Themmen, A.P. and Grootegeod, J.A. (1995):** Anti-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle and gonadotropin-induced follicle growth *Endocrinology*, 136: 4951–4962.
- 15- **Baarends, W. M.; van Helmond, M. J.; Post, M.; van der Schoot, P. J.; Hoogerbrugge, J. W.; de Winter, J. P.; Uilenbroek, J. T.; Karels, B.; Wilming, L. G.; Meijers, J. H. et al. (1994):** A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Müllerian duct. *Development* 120, 189–197.
- 16- **Banerjee, I.; Trueman, J.A.; Hall, C.M.; Price, D.A.; Patel, L.; Whatmore, A.J.; Hirschhorn, J.A.; Read, A.P.; Palmert, M.R. and Clayton, P.E. (2006):** Phenotypic variation in constitutional delay of growth and puberty: relationship to specific leptin and leptin receptor gene polymorphisms. *European Journal of Endocrinology*, 155:121–126.

- 17- **Barbara, D. P.; Bonneaud, N.; Boizet, B.; Desclozeaux, M.; Moniot, B.; Sudbeck, P. et al., (1998):** Direct interaction of SRY related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene. *Mol. Cell Biol.*, 18:6653-6665.
- 18- **Barbie, T. U.; Barbie, D. A.; MacLaughlin, D. T.; Maheswaran, S. and Donahoe, P. K. (2003):** Müllerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. *Proc. Natl. Acad. Sci. USA.*, 100:15601–15606.
- 19- **Bastida, M.G.; Rey, R.A.; Bergadá, I.; Bedecarrás, P.; Andreone, L.; del Rey, G.; Boywitt, A.; Ropelato, M.G.; Cassinelli, H.; Arcari, A.; Campo, S. and Gottlieb, S. (2007):** Establishment of testicular endocrine function impairment during childhood and puberty in boys with Klinefelter syndrome. *Clin. Endocrinol.*, 67:863–870.
- 20- **Bédécarrats, G.Y.; O'Neill, F.H.; Norwitz, E.R.; Kaiser, U.B. and Teixeira, J. (2003):** Regulation of gonadotropin gene expression by Müllerian inhibiting substance. *Proc. Natl. Acad. Sci. USA*, 100:9348-9353.
- 21- **Behringer, R. R.; Cate, R. L.; Froelick, G. J.; Palmiter, R. D. and Brinster, R. L. (1990):** Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. *Nature (London)*, 345: 167–170.
- 22- **Behringer, R.R.; Finegold, M.J. and Cate, R.L. (1994):** Müllerian-inhibiting substance function during mammalian sexual development. *Cell*, 79:415–425.
- 23- **Belville, C.; Jamin, S.P.; Picard, J.Y.; Josso, N. and di Clemente, N. (2005):** Role of type I receptors for anti-Müllerian hormone in the SMAT-1 Sertoli cell line. *Oncogene*; 24:4984–4992.
- 24- **Belville, C.; Josso, N. and Picard, J. Y. (1999):** Persistence of Müllerian derivatives in males. *Am. J. Med. Genet.*, 89: 218–223.
- 25- **Belville, C.; Van Vlijmen, H.; Ehrenfels, C.; Pepinsky, B.; Rezaie, A.R.; Picard, J.Y. et al. (2004):** Mutations of the anti-Müllerian hormone gene in patients with persistent müllerian duct syndrome: biosynthesis, secretion, and processing of the abnormal

- proteins and analysis using a three-dimensional model. *Mol. Endocrinol.*, 18:708-721.
- 26- **Berensztein, E.B.; Baquedano, M.S.; Pepe, C.M.; Costanzo, M.; Saraco, N.I.; Ponzio, R.; Rivarola, M.A. and Belgorosky, A. (2008):** Role of IGFs and insulin in the human testis during postnatal activation: differentiation of steroidogenic cells. *Pediatr. Res.*, 63:662–666.
- 27- **Bergadá, I.; Andreone, L.; Bedecarrás, P.; Ropelato, M.G.; Copelli, S.; Laissue, P.; Rey, R.A. and Campo, S. (2008):** Seminiferous tubule function in delayed-onset X-linked adrenal hypoplasia congenita associated with incomplete hypogonadotrophic hypogonadism. *Clin. Endocrinol. (Oxf.)*, 68:240–246.
- 28- **Bergadá, I.; Milani, C.; Bedecarrás, P.; Andreone, L.; Ropelato, M.G.; Gottlieb, S.; Bergadá, C.; Campo, S. and Rey, R.A. (2006):** Time course of the serum gonadotropin surge, inhibins, and anti-Müllerian hormone in normal newborn males during the first month of life. *J. Clin. Endocrinol. Metab.*, 91:4092–4098.
- 29- **Berst, M.J.; Dolan, L.; Bogdanowicz, M.; Stevens, M.M.; Chow, S. and Brandser, E.A. (2001):** Effect of knowledge of chronologic age on the variability of pediatric bone age determined using the Greulich and Pyle standards. *A.J.R.*, 176:507-510.
- 30- **Bertelloni, S.; Baroncelli, G.I.; Battini, R.; et al. (1995):** Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty. *J. Bone Miner. Res.*, 10:1488–1495.
- 31- **Bhagavath, B. and Layman, L.C. (2007):** The genetics of hypogonadotropic hypogonadism. *Semin. Reprod. Med.*, 25:272–286.
- 32- **Bhagavath, B.; Podolsky, R.H.; Ozata, M.; Bolu, E.; Bick, D.P.; Kulharya, A.; Sherins, R.J. and Layman, L.C. (2006):** Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism. *Fertil. Steril.*, 85:706–713.
- 33- **Biro, F.M.; Lucky, A.W.; Simbartl, L.A.; Barton, B.A.; Daniels, S.R. and Striegel-Moore, R. et al. (2003):** Pubertal maturation in girls and the relationship to anthropometric changes: pathways through puberty. *J. Pediatr.*, 142:643-646.
-

- 34- **Bonjour, J.P.; Theintz, G. and Law, F. et al. (1994):** Peak bone mass. *Osteoporos. Int.*; 4(1):7–13.
- 35- **Bonjour, J.P.; Theintz, G.; Buchs, B.; Slosman, D. and Rizolli, R. (1991):** Critical years of puberty for spinal and femoral bone mass accumulation during adolescence. *J. Clin. Endocrinol. Metab.*, 73:555–563.
- 36- **Bougnères, P.; François, M.; Pantalone, L.; Rodrigue, D.; Bouvattier, C.; Demesteere, E.; Roger, D. and Lahlou, N. (2008):** Effects of an early postnatal treatment of hypogonadotropic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and luteinizing hormone. *J. Clin. Endocrinol. Metab.*, 93:2202–2205.
- 37- **Boukari, K.; Meduri, G.; Brailly-Tabard, S.; Guibourdenche, J.; Ciampi, M.L.; Massin, N.; Martinerie, L.; Picard, J.Y.; Rey, R.; Lombès, M. and Young, J. (2009):** Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Müllerian hormone repression during early human testis development. *J. Clin. Endocrinol. Metab.*, 94:1818–1825.
- 38- **Bouvattier, C.; Carel, J.C.; Lecointre, C.; David, A.; Sultan, C.; Bertrand, A.M.; Morel, Y. and Chaussain, J.L. (2002):** Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the AR gene. *J. Clin. Endocrinol. Metab.*; 87:29–32.
- 39- **Brämswig, J. and Dübbers, A. (2009):** Disorders of pubertal development. *Dtsch. Arztebl. Int.*; 106(17): 295–304.
- 40- **Brown, D.C.; Stirling, H.F.; Butler, G.E.; Kelnar, C.J. and Wu, F.C. (1996):** Differentiation of normal male prepuberty and hypogonadotropic hypogonadism using an ultrasensitive luteinizing hormone assay. *Horm. Res.*, 46:83–87
- 41- **Bruning, J.C.; Gautam, D.; Burks, D.J.; Gillette, J.; Schubert, M.; Orban, P.C.; Klein, R.; Krone, W.; Müller-Wieland, D. and Kahn, C.R. (2000):** Role of brain insulin receptor in control of body weight and reproduction. *Science*, 289:2122–2125.
- 42- **Bull, R. K.; Edwards, P. D.; P M Kemp, P.M.; S Fry, S. and Hughes, I.A. (1999):** Bone age assessment: a large scale comparison of the Greulich and Pyle, and Tanner and Whitehouse (TW2) methods. *Arch. Dis Child.*, 81:172–173.

- 43- **Campbell, M.J. and Machin, D. (1993):** Medical statistics, a common sense approach. Wiley, J. and S. (eds). New York, pp. 266.
- 44- **Cate, R.L.; Mattaliano, R.J.; Hession, C.; Tizard, R.; Farber, N.M.; Cheung, A. et al., (1986):** Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. *Cell*, 45:685-698.
- 45- **Catlin, E.A.; Powell, S.M.; Manganaro, T.F.; Hudson, P.L.; Ragin, R.C.; Epstein, J. and Donahoe, P.K. (1990):** Sex-specific fetal lung development and Müllerian inhibiting substance. *Am. Rev. Respir. Dis.*, 141:466–470.
- 46- **Catteau-Jonard, S.; Pigny, P.; Reyss, A.C.; Decanter, C.; Poncelet, E. and Dewailly, D. (2007):** Changes in Serum Anti-Müllerian Hormone Level during Low-Dose Recombinant Follicular-Stimulating Hormone Therapy for Anovulation in Polycystic Ovary Syndrome. *J. Clin. Endocrinol. Metab.*, 92 (11): 4138-4143.
- 47- **Catteau-Jonard, S.; Soazik, P.J.; Leclerc, A.; Gonzales, J.; Dewailly, D. and di Clemente, N. (2008):** Anti-Müllerian hormone, its receptor, FSH receptor and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.*, 93:4456–4461.
- 48- **Cazorla, O.; Seck, M.; Pisselet, C.; Perreau, C.; Saumande, J.; Fontaine, J.; de Reviers, M. and Hochereau-de Reviers, M.T. (1998):** Anti-Müllerian hormone (AMH) secretion in prepubertal and adult rams. *J. Reprod. Fertil.*, 112:259–266.
- 49- **Chapman, S. M. (1972):** Ossification of the adductor sesamoid and the adolescent growth spurt. *Angle Orthodontist* 42: 236-245.
- 50- **Chemes, H.E. (2001):** Infancy is not a quiescent period of testicular development. *Int. J. Androl.*, 24:2–7.
- 51- **Chemes, H.E.; Rey, R.A.; Nistal, M.; Regadera, J.; Musse, M.; Gonzalez-Peramato, P. and Serrano, A. (2008):** Physiologic Androgen Insensitivity of the Fetal, Neonatal, and Early Infantile Testis Is Explained by the Ontogeny of the Androgen Receptor
-

- Expression in Sertoli Cells. *J. Clin. Endocrinol. Metab.*, 93:4408-4412.
- 52- **Cheung, C.C.; Thornton, J.E.; Kuijper, J.L.; Weigle, D.S.; Clifton, D.K. and Steiner, R.A. (1997):** Leptin is a metabolic gate for the onset of puberty in the female rat. *Endocrinology*, 138:855–858.
- 53- **Clarke, T. R.; Hoshiya, Y.; Yi, S. E.; Liu, X.; Lyons, K. M. and Donahoe, P. K. (2001):** Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. *Mol. Endocrinol.*, 15: 946–959.
- 54- **Cohane, G.H. (2001):** Body image in boys: a review of the literature. *Int. J. Eat. Disord.*; 29: 373–379.
- 55- **Cook, C.L.; Siow, Y.; Brenner, A.G. and Fallatt, M.E. (2002):** Relationship between serum Müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. *Fertil. Steril.*, 77:141–146
- 56- **Cook, C.L.; Siow, Y.; Taylor, S. and Fallat, M.E. (2000):** Serum Müllerian-inhibiting substance levels during normal menstrual cycles. *Fertil. Steril.*, 73: 859-861.
- 57- **Cooper, T.G.; Yeung, C.H.; Nashan, D. and Nieschlag, E. (1988):** Epididymal markers in human infertility. *J. Androl.*, 9: 91–101.
- 58- **Coughlin, J. P.; Donahoe, P. K.; Budzik, G. P. and MacLaughlin, D. T. (1987):** Müllerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase. *Mol. Cell Endocrinol.*, 49: 75-86.
- 59- **Coulam, C.B.; Adamson, S.C. and Annegers, J.F. (1986):** Incidence of premature ovarian failure. *Obstet. Gynecol.*, 67:604–606.
- 60- **Crowne, E.C.; Shalet, S.M.; Wallace, W.H.; Eminson, D.M. and Price, D.A. (1990):** Final height in boys with untreated constitutional delay in growth and puberty. *Archives of Disease in Childhood*, 65: 1109-1112.
-

- 61- Cundy, P.; Paterson, D.; Morris, L. and Foster, B. (1988):** Skeletal age estimation in leg length discrepancy. *J. Pediatr. Orthop.*, 8:513–515
- 62- Deffieux, X. and Antoine J.M. (2003):** Inhibins, activins, and anti-Müllerian hormone: structure, signaling pathways, role, and predictive value in reproductive medicine. *Gynecol. Obstet. Fertil.*, 31: 900 – 911.
- 63- Degros, V.; Cortet-Rudelli, C.; Soudan, B. and D Dewailly, D. (2003):** The human chorionic gonadotropin test is more powerful than the gonadotropin-releasing hormone agonist test to discriminate male isolated hypogonadotropic hypogonadism from constitutional delayed puberty. *European Journal of Endocrinology* 149:23–29.
- 64- Dehghani-Firouzabadi, R.; Tayebi, N. and Asgharnia, M. (2008):** Serum level of anti-Müllerian hormone in early follicular phase as a predictor of ovarian reserve and pregnancy outcome in assisted reproductive technology cycles. *Archives of Iranian Medicine*, 11(4):371-376.
- 65- De Koning, C.H.; McDonnell, J.; Themmen, A.P.; de Jong, F.H.; Homburg, R. and Lambalk, C.B. (2008):** The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls. *Hum. Reprod.*, 23:1416–1423.
- 66- De Meyts, E.; Jørgensen, N.; Graem, N.; Müller, J.; Cate, R.L. et al. (1999):** Expression of Anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. *J. Clin. Endocrinol. Metab.*, 84: 3836 – 3844.
- 67- De Vet, A.; Laven, J.S.; de Jong, F.H.; Themmen, A.P. and Fauser, B.C. (2002):** Anti-Müllerian hormone serum levels: a putative marker for ovarian aging. *Fertil. Steril.*, 77:357–362.
- 68- Demirjian, A.; Buschang, P.H.; Tanguay, R. and Kingnorth Patterson, D. (1985):** Interrelationships among measures of
-

- somatic, skeletal, dental and sexual maturity. *American Journal of Orthodontics*, 88:433-438.
- 69- **Dempfle, A.; Wudy, S.A.; Saar, K.; Hagemann, S.; Friedel, S.; Andre´ Scherag, A.; Berthold, L.D.; Alzen, G.; Gortner, L.; Blum, W.F.; Hinney, A.; Nünberg, P.; Schäfer, H. and Hebebrand, J. (2006):** Evidence for involvement of the vitamin D receptor gene in idiopathic short stature via a genome-wide linkage study and subsequent association studies. *Human Molecular Genetics*, 15:2772–2783.
- 70- **Dewailly, D.; Jonard, S.; Reyss, A.C.; Lefebvre, C.; Poncelet, E. and Pigny, P. (2007):** The excess in 2–5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome. *Hum. Reprod.*, 22:1562–1566.
- 71- **di Clemente, N.; Josso, N.; Gouedard, L. and Belville, C. (2003):** Components of the anti-Müllerian hormone signaling pathway in gonads. *Mol. Cell Endocrinol.*, 211:9-14.
- 72- **di Clemente, N.; Wilson, C.; Faure, E.; Boussin, L.; Carmillo, P.; Tizard, R.; Picard, J. Y.; Vigier, B.; Josso, N. and Cate, R. (1994 b):**Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. *Mol. Endocrinol.*, 8: 1006–1020.
- 73- **Dixon, J.; Wallace, A.M.; O’Toole, S. and Ahmed, S.F. (2007):** Prolonged human chorionic gonadotrophin stimulation as a tool for investigating and managing undescended testes. *Clin. Endocrinol. (Oxf)*, 67:816–821.
- 74- **Doneray H, Orbak Z. (2010):** Association between anthropometric hormonal measurements and bone mineral density in puberty and constitutional delay of growth and puberty. *West Indian Med. J.*, 9(2):125-30.
- 75- **Dresser, D.W.; Hacker, A.; Lovell-Badge, R. and Guerrier, D. (1995):** The genes for a spliceosome protein (SAP62) and the anti-Müllerian hormone (AMH) are contiguous. *Hum. Mol. Genet.*, 4:1613–1618.
-

- 76- Duke, P.M.; Carlsmith, J.M.; Jennings, D. et al. (1982): Educational correlates of early and late sexual maturation in adolescence. *J. Pediatr.*, 100:633-637.
- 77- Dunkel, L. (2009): Update on the role of aromatase inhibitors in growth disorders. *Horm Res*; 1: 57–63.
- 78- Dupertuis, C. W.; Atkinson, W. B. and Elftman, H. (1945): Sex differences in pubic hair distribution. *Human Biology*, 17:137.
- 79- Durlinger, A.L.; Gruijters, M.J.; Kramer, P.; Karels, B.; Kumar, T.R.; Matzuk, M.M.; Rose, U.M.; de Jong, F.H.; Uilenbroek, J.T.; Grootegoed, J.A. and Themmen, A.P. (2001): Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. *Endocrinology*, 142: 4891-4899.
- 80- Durlinger, A.L.; Gruijters, M.J.; Kramer, P.; Karels, B.; Ingraham, H.A.; Nachtigal, M.W.; Uilenbroek, J.T.; Grootegoed, J.A. and Themmen, A.P. (2002 a): Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. *Endocrinology*, 143:1076–1084.
- 81- Durlinger, A.L.; Kramer, P.; Karels, B.; de Jong, F.H.; Uilenbroek, J.T. and Grootegoed, J.A. et al. (1999): Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. *Endocrinology*, 14: 5789-5796.
- 82- Durlinger, A.L.; Visser, J.A. and Themmen, A.P. (2002 b): Regulation of ovarian function: the role of anti-Müllerian hormone. *Reproduction*, 124:601–609.
- 83- Dutertre, M.; Gouedard, L.; Xavier, F.; Long, W.Q.; di Clemente, N.; Picard, J.Y. and Rey, R. (2001): Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice. *Endocrinology*, 142: 4040–4046.
- 84- Duvilla, E.; Lejeune, H.; Paviot, B.T.; Perret, A.G.; Tostain, J. and Levy, R. (2008): Significance of inhibin B and anti-Müllerian hormone in seminal plasma: a preliminary study. *Fertil. Steril.*, 89(2):444-8.
-

- 85- Eakman, G. D.; Dallas, J. S.; Ponder, S. W. and Keenan, B. S. (1996):** The effects of testosterone and dihydrotestosterone on hypothalamic regulation of growth hormone secretion. *J. Clin. Endocrinol. Metab.*, 81:1217–1223.
- 86- Eldar-Geva, T.; Margalioth, E.J.; Gal, M.; Ben-Chetrit, A.; Algur, N.; Zylber-Haran, E.; Brooks, B.; Huerta, M. and Spitz, I.M. (2005):** Serum anti-Müllerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. *Hum. Reprod.*, 20:1814–1819.
- 87- El-Eshmawy, M.M.; Abdel Aal, I.A. and El hawary, A.K. (2010):** Association of ghrelin and leptin with reproductive hormones in constitutional delay of growth and puberty. *Reproductive Biology and Endocrinology*, 8:153-158.
- 88- El-Halawaty, S.; Azab, H.; Said, T.; Bedaiwy, M.; Amer, M.; Kamal, M. and Al-Inany, H. (2011):** Assessment of male serum anti-Müllerian hormone as a marker of spermatogenesis and ICSI outcome. *Gynecol. Endocrinol.*, 27(6):401-5.
- 89- Fallat, M.E.; Siow, Y.; Belker, A.M.; Boyd, J.K.; Yoffe, S. and MacLaughlin, D.T. (1996):** The presence of Müllerian inhibiting substance in human seminal plasma. *Hum. Reprod.*, 11: 2165–2169.
- 90- Fanchin, R.; Schonauer, L.M.; Righini, C.; Guibourdenche, J.; Frydman, R. and Taieb, J. (2003):** Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, FSH, and LH on day 3. *Hum. Reprod.*, 18: 323 – 327.
- 91- Fanchin, R.; Taieb, J.; Lozano, D.H.; Ducot, B.; Frydman, R. and Bouyer, J. (2005):** High reproducibility of serum anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of follicular status. *Hum. Reprod.*, 20:923–927.
- 92- Farag, T.I. (1993):** Familial persistent müllerian duct syndrome in Kuwait and neighboring populations. *Am. J. Med. Genet.*, 47:432-434.
-

- 93- Farooqi, I.S.; Jebb, S.A.; Langmack, G.; Lawrence, E.; Cheetham, C.H.; Prentice, A.M.; Hughes, I.A.; McCamish, M.A. and O’Rahilly, S. (1999): Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *New England Journal of Medicine*, 341:879–884.
- 94- Fénichel, P.; Rey, R.; Poggioli, S.; Donzeau, M.; Chevallier, D. and Pointis, G. (1999): Anti-Müllerian hormone as a seminal marker for spermatogenesis in non-obstructive azoospermia. *Hum. Reprod.*, 14: 2020–2024.
- 95- Feyereisen, E.; Mendez Lozano, D.H.; Taieb, J.; Hesters, L., Frydman, R. and Fanchin, R. (2006): Anti-Müllerian hormone: clinical insights into a promising marker of ovarian follicular status. *Reprod Biomed. Online*, 12:695–703.
- 96- Ficicioglu, C.; Kutlu, T.; Baglam, E. and Bakacak, Z. (2006): Early follicular anti-Müllerian hormone as an indicator of ovarian reserve. *Fertil. Steril.*, 85:592–596.
- 97- Finkelstein, J.S.; Klibanski, A. and Neer, R.M. (1996): A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. *J. Clin. Endocrinol. Metab.*, 81:1152–1155.
- 98- Franks, S.; Stark, J.E. and Hardy, K. (2008): Follicle dynamics and anovulation in polycystic ovary syndrome. *Human Reproduction Update*, 14:367–378.
- 99- Fujisawa, M.; Yamasaki, T.; Okada, H. and Kamidono, S. (2002): The significance of anti-Müllerian hormone concentration in seminal plasma for spermatogenesis. *Hum. Reprod.*, 17: 968–70.
- 100- Gaethofs, M.; Verdonck, A.; Carels, C. and de Zegher, F. (1999): Delayed dental age in boys with constitutionally delayed puberty. *European Journal of Orthodontics*, 21:711-715.
- 101- Garcia-Mayor, R.V.; Andrade, M.A.; Rios, M.; Lage, M.; Dieguez, C. and Casanueva, F.F. (1997): Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary-gonadal hormones, and pubertal stage. *J. Clin. Endocrinol. Metab.*, 82:2849–2855.
-

- 102- **Gilli, G. (1996):** The assessment of skeletal maturation. *Horm. Res.*, 45(2):49-52.
- 103- **Gordon, M.; Crouthamel, C.; Post, E.M. and Richman, R.A. (1982):** Psychosocial aspects of constitutional short stature: social competence, behaviour problems, self-esteem and family functioning. *J. Pediatr.*, 101:477-480.
- 104- **Gouedard, L.; Chen, Y. G.; Thevenet, L.; Racine, C.; Borie, S.; Lamarre, I.; Josso, N.; Massague, J. and di Clemente, N. (2000):** Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. *J. Biol. Chem.*, 275: 27973–27978.
- 105- **Goulis, D.G.; Iliadou, P.K.; Tsametis, C.; Gerou, S.; Tarlatzis, B.C.; Bontis, I.N. and Papadimas, I. (2008):** Serum anti-Müllerian hormone levels differentiate control from subfertile men but not men with different causes of subfertility. *Gynecological Endocrinology*, 24(3): 158–160.
- 106- **Goulis, D.G.; Tsametis, C.; Iliadou, P.K.; Polychronou, P.; Kantartzi, P.D.; Tarlatzis, B.C.; Bontis, I.N. and Papadimas, I. (2009):** Serum inhibin B and anti-Müllerian hormone are not superior to follicle-stimulating hormone as predictors of the presence of sperm in testicular fine-needle aspiration in men with azoospermia. *Fertil. Steril.*, 91(4):1279-84.
- 107- **Graber, J.A.; Seeley, J.R.; Brooks-Gunn, J. and Lewinsohn, P.M. (2004):** Is pubertal timing associated with psychopathology in young adulthood. *J. Am. Acad. Child Adolesc. Psychiatry*, 43:718-726.
- 108- **Gran, S.M.; Lewis, A.B. and Blizzard, R.M. (1965):** Endocrine factors in dental development. *Journal of Dental Research*, 44:243-258.
- 109- **Grasemann, C.; Wessels, H.T.; Knauer-Fischer, S.; Richter-Unruh, A. and Hauffa, B.P. (2004):** Increase of serum leptin after short-term pulsatile GnRH administration in children with delayed puberty. *European Journal of Endocrinology* 150:691–698.
- 110- **Grave, K. C. and Brown, T. (1976):** Skeletal ossification and the adolescent growth spurt. *American Journal of Orthodontics* 69: 611-619.
-

- 111- **Greulich WW, Pyle SI. (1959):** Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Stanford, CA: Stanford University Press.
- 112- **Greulich, W.W.; Pyle, S.I. and Waterhouse, A.M. (1971):** A radiographic standard of reference for the growing hand and wrist. Chicago: Case Western Reserve University.
- 113- **Grinspon, R.P. and Rey, R.A. (2010):** Anti-Müllerian hormone and Sertoli cell function in paediatric male hypogonadism. *Horm. Res. Paediatr.*, 73:81-92.
- 114- **Grob, A. (2003):** Erwachsen werden: Entwicklungspsychologie des Jugendalters: Beltz PVU.
- 115- **Grossman, M.P.; Nakajima, S.T.; Fallat, M.E. and Siow, Y. (2008):** Müllerian inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. *Fertil. Steril.*, 89:1364–1370.
- 116- **Gruijters, M.J.; Visser, J.A.; Durlinger, A.L. and Themmen, A.P. (2003):** Anti-Müllerian hormone and its role in ovarian function. *Mol. Cell Endocrinol.*, 211: 85 – 90.
- 117- **Guerrier, D.; Boussin, L.; Mader, S.; Josso, N.; Kahn, A.; Picard, J.Y. (1990):** Expression of the gene for anti-Müllerian hormone. *J. Reprod. Fertil.*, 88:695-706.
- 118- **Guerrier, D.; Tran, D.; Vanderwinden, J.M.; Hideux, S.; Van Outryve, L. and Legeai, L. (1989):** The persistent Müllerian duct syndrome: a molecular approach. *J. Clin. Endocrinol. Metab.*, 68:46–52.
- 119- **Guibourdenche, J.; Lucidarme, N.; Chevenne, D.; Rigal, O.; Nicolas, M.; Luton, D.; Leger, J.; Porquet, D. and Noel, M. (2003):** Anti-Müllerian hormone levels in serum from human foetuses and children: pattern and clinical interest. *Mol. Cell Endocrinol.*, 211:55–63.
- 120- **Ha, T.U.; Segev, D.L. and Barbie, D. et al. (2000):** Müllerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. *Journal of Biological Chemistry*, 275(37):101–109.
-

- 121- Hägg, U. and Taranger, J. (1982): Maturation indicators and the growth spurt. *American Journal of Orthodontics*, 82:239-309.
- 122- Han, J.C.; Balagopal, P.; Sweeten, S.; Darmaun, D. and Mauras, N. (2006): Evidence for hypermetabolism in boys with constitutional delay of growth and maturation. *J. Clin. Endocrinol. Metab.*, 91:2081–2086.
- 123- Hassel, B. and Farman, A. G. (1995): Skeletal maturation evaluation using cervical vertebrae. *American Journal of Orthodontics and Dentofacial Orthopedics* 107: 58-66.
- 124- Hehenkamp, W.J.; Looman, C.W.; Themmen, A.P., de Jong, F.H.; velde, E.R. and Broekmans, F.J. (2006): Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. *J. Clin. Endocrinol. Metab.*, 91:4057–4063.
- 125- Hiney, J.K.; Srivastava, V.; Nyberg, C.L.; Ojeda, S.R. and Dees, W.L. (1996): Insulin-like growth factor I of peripheral origin acts centrally to accelerate the initiation of female puberty. *Endocrinology*, 137:3717–3728.
- 126- Hirsch, H.J.; Eldar-Geva, T.; Benarroch, F.; Rubinstein, O. and Gross-Tsur, V. (2009): Primary testicular dysfunction is a major contributor to abnormal pubertal development in males with Prader-Willi syndrome. *J. Clin. Endocrinol. Metab.*, 94:2262–2268.
- 127- Horlick, M.B.; Rosenbaum, M.; Nicolson, M.; Levine, L.S.; Fedun, B.; Wang, J.; Pierson, R.N. and Leibel, R.L. (2000): Effect of puberty on the relationship between circulating leptin and body composition. *J. Clin. Endocrinol. Metab.*, 85:2509–2518.
- 128- Hoshiya, M.; Christian, B.P.; Cromie, W.J.; Kim, H.; Zhan, Y.; MacLaughlin, D.T. and Donahoe, P.K. (2003a): Persistent Müllerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene. *A. Clin. Mol. Teratol.*, 67:868–874.
- 129- Hoshiya, Y.; Gupta, V.; Segev, D.L.; Hoshiya, M.; Carey, J.L.; Sasur, L.M.; Tran, T.T.; Ha, T.U. and Maheswaran, S. (2003b): Müllerian inhibiting substance induces NF kappa B signaling in breast and prostate cancer cells. *Mol. Cell Endocrinol.*, 211:43–49.
-

- 130- Hossain, A. and Saunders, G.F. (2003):** Role of Wilm's tumor 1 (WT1) in the transcriptional regulation of the Müllerian-inhibiting substance promoter. *Biol. Reprod.*, 69:1808–1814.
- 131- Houston, W. J.; Miller, J. C. and Tanner, J. M. (1979):** Prediction of the timing of the adolescent growth spurt from ossification events in hand-wrist films. *British Journal of Orthodontics*, 6: 142-152.
- 132- Hsieh, C.W.; Jong, T.L.; Chou, Y.H. and Tiu, C.M. (2007):** Computerized geometric features of carpal bone for bone age estimation. *Chinese Medical Journal*, 120(9):767-770.
- 133- Hutson, J.M.; Hasthorpe, S. and Heyns, C.F. (1997):** Anatomical and functional aspects of testicular descent and cryptorchidism. *Endocr. Rev.*, 18:259-280.
- 134- Imbeaud, S.; Belville, C.; Messika-Zeitoun, L.; Rey, R.; di Clemente, N.; Josso, N. et al., (1996):** A 27 base-pair deletion of the anti-müllerian type II receptor gene is the most common cause of the persistent müllerian duct syndrome. *Hum. Mol. Genet.*, 5:1269-1277.
- 135- Imbeaud, S.; Faure, E.; Lamarre, I.; Mattei, M. G.; di Clemente, N.; Tizard, R.; Carre-Eusebe, D.; Belville, C.; Tragethon, L.; Tonkin, C. et al. (1995a):** Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor. *Nat. Genet.*, 11: 382–388.
- 136- Imbeaud, S.; Rey, R.; Berta, P.; Chaussain, J.L.; Wit, J.M.; Lustig, R.H. et al. (1995b):** Testicular degeneration in three patients with the persistent müllerian duct syndrome. *Eur. J. Pediatr.* 154:187-190.
- 137- Isikoglu, M.; Ozgur, K.; Oehninger, S.; Ozdem, S. and Seleker, M. (2006):** Serum anti-Müllerian hormone levels do not predict the efficiency of testicular sperm retrieval in men with non-obstructive azoospermia. *Gynecol. Endocrinol.*, 22: 256–60.
- 138- Ivell, R. and Hartung, S. (2003):** The molecular basis of cryptorchidism. *Mol. Hum. Reprod.*, 9:175–181.
- 139- Jamin, S. P.; Arango, N. A.; Mishina, Y.; Hanks, M. C. and Behringer, R. R. (2002):** Requirement of *Bmpr1a* for Müllerian

- duct regression during male sexual development. *Nat. Genet.*, 32: 408–410.
- 140- Jamin, S. P.; Arango, N. A.; Mishina, Y.; Hanks, M. C. and Behringer, R. R. (2003):** Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression. *Mol. Cell Endocrinol.*, 211: 15-19.
- 141- Jonard, S. and Dewailly, D. (2004):** The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. *Hum. Reprod. Update*, 10:107–117.
- 142- Josso, N.; Belville, C.; di Clemente, N. and Picard, J.Y. (2005):** AMH and AMH receptor defects in persistent Müllerian duct syndrome. *Hum. Reprod. Update*, 11:351–356.
- 143- Josso, N.; Belville, C. and Picard, J.Y. (2003):** Persistence of Müllerian derivatives in males. In Fauser BCJM (ed) *Molecular Biology in Reproductive Medicine*. pp 575–586.
- 144- Josso, N.; di Clemente, N. and Gouedard, L. (2001):** Anti-Müllerian hormone and its receptors. *Mol. Cell. Endocrinol.*, 179:25–32.
- 145- Josso, N.; Fekete, C.; Cachin, O.; Nezelof, C. and Rappaport, R. (1983):** Persistence of Müllerian ducts in male pseudohermaphroditism, and its relationship to cryptorchidism. *Clin. Endocrinol.*, 19:247–258.
- 146- Josso, N.; Lamarre, I.; Picard, J. Y.; Berta, P.; Davies, N.; Morichon, N.; Peschanski, M. and Jeny, R. (1993):** Anti-Müllerian hormone in early human development. *Early Hum. Dev.*, 33: 91–99.
- 147- Josso, N.; Picard, J.Y.; Rey, R.; and Clemente, N. (2006):** Testicular anti-Müllerian hormone: history, genetics, regulation and clinical applications. *Pediatr. Endocrinol. Rev.*, 3:347–58.
- 148- Jost, A. (1953):** Problems of fetal endocrinology: the gonadal and hypophyseal hormones. *Recent Prog. Horm. Res.*, 8:379-418.

- 149- Juul, A. (2003):** Serum levels of insulin-like growth factor I and its binding proteins in health and disease. *Growth Hormone and IGF Research*, 13:113-170.
- 150- Kalra, S.P.; Dube, M.G.; Pu, S.; Xu, B.; Horvath, T.L. and Kalra, P.S. (1999):** Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. *Endocrine Reviews*, 20:68–100.
- 151- Karlberg, P. and Taranger, J. (1976):** The somatic development of children in a Swedish urban community. *Acta. Pediatr. Scand. Suppl.*; 258:1–48.
- 152- Kauschansky, A.; Dickerman, Z.; Phillip, M.; Weintrob, N. and Strich, D. (2002):** Use of GnRH agonist and human chorionic gonadotrophin tests for differentiating constitutional delayed puberty from gonadotrophin deficiency in boys. *Clin. Endocrinol. (Oxf)*, 56:603–607.
- 153- Kaya, C.; Pabuccu, R. and Satioglu, H. (2010):** Serum antimüllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction. *Fertil. Steril.*, 94: 2202-2207.
- 154- Keenan, B.S.; Richards, G.E.; Ponder, S.W.; Dallas, J.S.; Nagamani, M. and Smith, E.R. (1993):** Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. *J. Clin. Endocrinol. Metab.*, 76:996–1001.
- 155- Keller, E.; Sather, A. and Hayles, B. (1970):** Dental and skeletal development in various endocrine and metabolic diseases. *Journal of the American Dental Association*, 81:415-419.
- 156- Kerrigan, J.R.; Martha, P.M.; Blizzard, R.M. et al. (1990):** Variations of pulsatile growth hormone release in healthy short prepubertal boys. *Pediatr. Res.*, 28:11–14.
-

- 157- **Kerrigan, J.R. and Rogol, A.D. (1992):** The impact of gonadal steroid hormone action on growth hormone secretion during childhood and adolescence. *Endocrine Review*, 13:281-289.
- 158- **Kevenaar, M.E.; Meerasahib, M.F.; Kramer, P.; Lang-Borg, B.M.; de Jong, F.H.; Groome, N.P.; Themmen, A.P. and Visser, J.A. (2006):** Serum anti-Müllerian hormone levels reflect the size of the primordial follicle pool in mice. *Endocrinology*, 147:3228–3234.
- 159- **Kevenaar, M.E.; Laven, S.E.; Lie Fong, S.; Uitterlinden, A.G.; de Jong, F.H.; Themmen, P.N. and Visser, J.A. (2008):** A functional AMH polymorphism is associated with follicle number and androgen levels in polycystic ovary syndrome patients. *J. Clin. Endocrinol. Metab.*, 93:1310–1316.
- 160- **Kevenaar, M.E.; Themmen, P.N.; Kerkwijk, J.V.; Valkenburg, O.; Uitterlinden, A.G.; de Jong, F.H.; Laven, S.E. and Visser, J.A. (2009):** Variants in the ACVR1 gene are associated with AMH levels in women with polycystic ovary syndrome. *Human Reproduction*, 24 (1):241–249.
- 161- **Kimura, M.; Itoh, N.; Takagi, S.; Sasao, T.; Takahashi, A.; Masumori, N. and Tsukamoto, T. (2003):** Balance of apoptosis and proliferation of germ cells related to spermatogenesis in aged men. *J. Androl.*, 24(2):185-91.
- 162- **Klein, K.O.; Martha, P.M. and Blizzard, R.M. et al. (1996a):** A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. II. Estrogen levels as determined by an ultrasensitive bioassay. *J. Clin. Endocrinol. Metab.*, 81(9):3203–3207.
- 163- **Klein, N.A.; Illingworth, P.J.; Groome, N.P.; McNeilly, A.S.; Battaglia, D.E. and Soules, M.R. (1996b):** Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. *J. Clin. Endocrinol. Metab.*, 81:2742–2745.
-

- 164- Knauff, E.A.; Eijkemans, M.J.; Lambalk, C.B.; ten Kate-Booij, M.J.; Hoek, A.; Beerendonk, C.C.; Laven, J.S.; Goverde, A.J.; Broekmans, F.J.; Themmen, A.P., de Jong, F.H. and Fauser, B.C. (2009):** Anti-Müllerian hormone, inhibin b, and antral follicle count in young women with ovarian failure. *J. Clin. Endocrinol. Metab.*, 94: 786–792.
- 165- Knobil, E. (1980):** The neuroendocrine control of the menstrual cycle. *Recent Prog. Horm. Res.*, 36:53–88.
- 166- Kobayashi, A.; Stewart, C.A.; Wang, Y.; Fujioka, K.; Thomas, N.C.; Jamin, S.P. and Behringer, R.R. (2011):** {beta}-Catenin is essential for Mullerian duct regression during male sexual differentiation. *Development*, 138(10):1967-75.
- 167- Kow, L.M.; Florea, C.; Schwanzel-Fukuda, M.; Devidze, N.; Kami Kia, H.; Lee, A.; Zhou, J.; Maclaughlin, D.; Donahoe, P. and Pfaff, D. (2007):** Development of a sexually differentiated behavior and its underlying CNS arousal functions. *Curr. Top. Dev. Biol.*, 79:37–59.
- 168- Krauss, S.; Zhang, C.Y.; Lowell, B.B. (2005):** The mitochondrial uncoupling-protein homologues. *Nat. Rev. Mol. Cell. Biol.*, 6:248–261.
- 169- Krishnan, A.V.; Moreno, J.; Nonn, L.; Malloy, P.; Swami, S.; Peng, L.; Peehl, D.M. and Feldman, D. (2007):** Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. *J. Steroid Biochem. Mol. Biol.*, 103:694–702.
- 170- Krupa, B. and Miazgowski, T. (2005):** Bone mineral density and markers of bone turnover in boys with constitutional delay of growth and puberty. *The Journal of Clinical Endocrinology & Metabolism* 90(5):2828–2830.
- 171- Kulin, H.E.; Bwibo, N.; Mutie, D. and Santner, S.J. (1984):** Gonadotropin excretion during puberty in malnourished children. *J. Pediatr.*, 105:325–328.
-

- 172- **Kulin, H.E.; Santen R.J. (1986):** Delayed adolescence. In: Kohler PO, ed. Clinical endocrinology. New York: John Wiley, Sons; 342.
- 173- **Kwee, J.; Schats, R.; McDonnell, J.; Shoemaker, J. and Lambalk, C.B. (2006):** The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyper responders to in vitro fertilization. *Fertil. Steril.*, 85:1714–1722.
- 174- **La Marca, A.; Pati, M.; Orvieto, R.; Stabile, G.; Artenisio, A. C. and Volpe, A. (2006):** Serum anti-Müllerian hormone levels in women with secondary amenorrhea. *Fertil. Steril.*, 85:1547–1549
- 175- **La Marca, A.; Orvieto, R.; Giulini, S.; Jasonni, V.M.; Volpe, A. and De Leo, V. (2004):** Müllerian inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. *Fertil. Steril.*, 82:970–972.
- 176- **La Marca, A. and Volpe, A. (2007):** The Anti-Müllerian hormone and ovarian cancer. *Hum. Reprod. Update*, 13:265–273.
- 177- **LaFranchi, S.; Cheryl, E.H.; Mandel, S.H. (1991):** Constitutional delay of growth: expected versus final adult height. *Pediatrics*, 87:82–87.
- 178- **Lamparski, D. (1972):** Skeletal age assessment utilizing cervical vertebrae. Thesis. University of Pittsburgh, Pennsylvania.
- 179- **Lampit, M. and Hochberg, Z. (2003):** Androgen therapy in constitutional delay of growth. *Horm. Res.*, 59:270-275.
- 180- **Lane, A. H.; Lee, M. M.; Fuller, A. F.; Kehas, D. J.; Donahoe, P. K. and MacLaughlin, D. T. (1999):** Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. *Gynecol. Oncol.* 73:51–55.
- 181- **Largo, R.H.; Gasser, T. and Prader, A. et al. (1978):** Analysis of the adolescent growth spurt using smoothing spline functions. *Ann. Hum. Biol.*; 5(5):421–434.
-

- 182- Laven, J.S.; Mulders, A.G.; Visser, J.A.; Themmen, A.P.; De Jong, F.H. and Fauser, B.C. (2004):** Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. *J. Clin. Endocrinol. Metab.*, 89:318–323.
- 183- Layman, L.C.; Lee, E.J.; Peak, D.B.; Namnoum, A.B.; Vu, K.V.; van Lingen, B.L.; Gray, M.R.; McDonough, P.G.; Reindollar, R.H.; and Jameson, J.L. (1997):** Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone β -subunit gene. *N. Engl. J. Med.*, 337:607–611.
- 184- Lechleider, R.J.; Ryan, J.L.; Garrett, L.; Eng, C.; Deng, C.; Wynshaw-Boris, A. and Roberts, A.B. (2001):** Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. *Dev. Biol.*, 240:157–167.
- 185- Lee, M.M. and Donahoe, P.K. (1993):** Mullerian inhibiting substance: a gonadal hormone with multiple functions. *Endocr. Rev.*, 14:152–164.
- 186- Lee, M.M.; Misra, M.; Donahoe, P.K.; MacLaughlin, D.T. (2003):** MIS/AMH in the assessment of cryptorchidism and intersex conditions. *Mol. Cell. Endocrinol.*, 211: 91–98.
- 187- Lee, W.S.; Otsuka, F.; Moore, R.K. and Shimasaki, S. (2001):** Effect of bone morphogenetic protein-7 on folliculogenesis and ovulation in the rat. *Biol. Reprod.*, 65:994–999.
- 188- Lee, M. M.; Seah, C. C.; Masiakos, P. T.; Sottas, C. M.; Preffer, F. I.; Donahoe, P. K.; MacLaughlin, D. T. and Hardy, M. P. (1999):** Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells. *Endocrinology*, 140: 2819–2827.
- 189- Lee, W.S.; Yoon, S.J.; Yoon, T.K. Cha, K.Y.; Lee, S.H.; Shimasaki, S.; Lee, S. and Lee, K.A. (2004):** Effects of bone morphogenetic protein-7 (BMP-7) on primordial follicular growth in the mouse ovary. *Mol Reprod. Dev.*, 69: 159–163.
- 190- Levine, J.A.; Lanningham-Foster, L.M.; McCrady, S.K.; Krizan, A.C.; Olson, L.R.; Kane, P.H.; Jensen, M.D. and Clark, M.M. (2005):** Interindividual variation in posture allocation: possible role in human obesity. *Science* 307:584–586.
-

- 191- Lin, L.; Philibert, P.; Ferraz-de-Souza, B.; Kelberman, D.; Homfray, T.; Albanese, A.; Molini, V.; Sebire, N.J.; Einaudi, S.; Conway, G.S.; Hughes, I.A.; Jameson, J.L.; Sultan, C.; Dattani, M.T. and Achermann, J.C. (2007): Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46XY disorders of sex development with normal adrenal function. *J. Clin. Endocrinol. Metab.*, 92:991–999.
- 192- Long, W. Q.; Ranchin, V.; Pautier, P.; Belville, C.; Denizot, P.; Cailla, H.; Lhomme, C.; Picard, J. Y.; Bidart, J. M. and Rey, R. (2000): Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. *J. Clin. Endocrinol. Metab.*, 85:540–544.
- 193- Lukas-Croisier, C.; Lasala, C.; Nicaud, J.; Bedecarrás, P.; Kumar, T.R.; Dutertre, M.; Matzuk, M.M.; Picard, J.Y.; Josso, N. and Rey, R. (2003): Follicle-stimulating hormone increases testicular anti-müllerian hormone production through Sertoli cell proliferation and a nonclassical cyclic adenosine 5'-monophosphate-mediated activation of the AMH gene. *Mol. Endocrinol.*, 17:550–561.
- 194- Lyritis, G.P.; Schoenau, E.; Sarantavos, G. (2000): Osteopenic syndromes in the adolescent female. *Ann. NY. Acad. Sci.*, 900:403–405.
- 195- Ma, X.; Dong, Y.; Matzuk, M.M. and Kumar, T.R. (2004): Targeted disruption of luteinizing hormone β -subunit leads to hypogonadism, defects in gonadal steroidogenesis, and infertility. *Proc Natl. Acad. Sci. USA.*, 101:17294–17299.
- 196- Mahutte, N.G. and Arici, A. (2007): Role of gonadotropin-releasing hormone antagonists in poor responders. *Fertil. Steril.*, 87:241–249.
- 197- Mainieri, A.S. and Elnecave R.H. (2003): Usefulness of the free α subunit to diagnose hypogonadotropic hypogonadism. *Clin. Endocrinol. (Oxf)*, 59:307–313.
- 198- Malloy, P.J., Peng, L.; Wang, J. and Feldman, D. (2009): Interaction of the Vitamin D Receptor with a Vitamin D Response Element in the Müllerian-Inhibiting Substance (MIS) Promoter:
-

- Regulation of MIS Expression by Calcitriol in Prostate Cancer Cells. *Endocrinology*, 150(4):1580–1587.
- 199- Marques-Lopes, I.; Forga, L. and Martinez, J.A. (2003):** Thermogenesis induced by a high-carbohydrate meal in fasted lean and overweight young men: insulin, body fat, and sympathetic nervous system involvement. *Nutrition*, 19:25–29.
- 200- Masiakos, P. T.; MacLaughlin, D. T.; Maheswaran, S.; Teixeira, J.; Fuller, A. F.; Shah, P. C.; Kehas, D. J.; Kenneally, M. K.; Dombkowski, D. M.; Ha, T. U.; Preffer, F. I. and Donahoe, P. K. (1999):** Human ovarian cancer, cell lines, and primary ascites cells express the human Müllerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. *Clin. Cancer Res.*, 5: 3488–3499.
- 201- Mauras, N.; O'Brien, K.O. and Welch, S. et al. (2000):** Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. *J. Clin. Endocrinol. Metab.*, 85(4):1686–1694.
- 202- Maymon, B.B.; Yogev, L.; Paz, G.; Kleiman, S.E.; Schreiber, L.; Botchan, A. et al. (2002):** Sertoli cell maturation in men with azoospermia of different etiologies. *Fertil. Steril.*, 77:904–909.
- 203- McGee, E.A. and Hsueh, A.J. (2000):** Initial and cyclic recruitment of ovarian follicles. *Endocrine Reviews*, 21:200–214.
- 204- Metzger, D.L. and Kerrigan, J.R. (1994):** Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence. *J. Clin. Endocrinol. Metab.*, 79(2):513–518.
- 205- Michaud, P.A., Suris, J.C. and Deppen, A. (2006):** Gender-related psychological and behavioural correlates of pubertal timing in a national sample of Swiss adolescents. *Molecular and Cellular Endocrinology*, 254-255:172-178.
- 206- Mishina, Y.; Rey, R.; Finegold, M. J.; Matzuk, M. M.; Josso, N.; Cate, R. L. and Behringer, R. R. (1996):** Genetic analysis of

- the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. *Genes Dev.* 10: 2577–2587.
- 207- **Misra, M.; MacLaughlin, D.T.; Donahoe, P.K. and Lee, M.M. (2002):** Measurement of Müllerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism. *J. Clin. Endocrinol. Metab.*, 87:3598–3602.
- 208- **Misra, M.; MacLaughlin, D.T.; Donahoe, P.K. and Lee, M.M. (2003):** The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization. *J. Clin. Endocrinol. Metab.*, 88:787–792.
- 209- **Mitchell, V.; Boitrelle, F.; Pigny, P.; Robin, G.; Marchetti, C.; Marcelli, F. and Rigot, J.M. (2010):** Seminal plasma levels of anti-Müllerian hormone and inhibin B are not predictive of testicular sperm retrieval in nonobstructive azoospermia: a study of 139 men. *Fertil. Steril.*, 94(6):2147-50.
- 210- **Moreira-Andre's, M.N.; Cañizo, F.J.; de la Cruz, F.J.; de la Cámara, A.G. and Hawkins, F.G. (1998):** Bone mineral status in prepubertal children with constitutional delay of growth and puberty. *European Journal of Endocrinology*, 139:271–275.
- 211- **Moreira-Andre's, M.N.; Papapietro, K.; Cañizo, F.J.; Rejas, J.; Larrodera, L. and Hawkins, F.G. (1995):** Correlations between bone mineral density, insulin-like growth factor I and auxological variables. *European Journal of Endocrinology*, 132:573–579.
- 212- **Moseley, C.F. (1989):** Assessment and prediction in leg-length discrepancy. *Instr. Course. Lect.*, 38:325–330.
- 213- **Moshang, J.T.; Marx, B.S.; Cara, J.F. and Snyder, P.J. (1985):** The prolactin response to thyrotropin-releasing hormone does not distinguish teenaged males with hypogonadotropic hypogonadism from those with constitutional delay of growth and development. *J. Clin. Endocrinol. Metab.*, 61:1211–1213.
- 214- **Mostafa, T.; Amer, M.K.; Abdel-Malak, G.; Abdel-Nsser, T.; Wael Zohdy, W.; Shedeed Ashour, S.; Dina El-Gayar, D. and Awad, H.H. (2007):** Seminal plasma anti-Müllerian hormone level correlates with semen parameters but does not predict success of testicular sperm extraction (TESE). *Asian J Androl*, 9(2): 265–270.
-

- 215- **Mounzih, K.; Lu, R. and Chehab, F.F. (1997):** Leptin treatment rescues the sterility of genetically obese ob/ob males. *Endocrinology*, 138:1190–1193.
- 216- **Nachtigal, M.W. and Ingraham, H.A. (1996):** Bioactivation of Müllerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. *Proc. Natl. Acad. Sci. USA*, 93:7711-7716.
- 217- **Nakhuda, G.S.; Chu, M.C.; Wang, J.G.; Sauer, M.V. and Lobo, R.A. (2006):** Elevated serum Müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilisation. *Fertil. Steril.*, 85:1541–1543.
- 218- **Nathan, B.M. and Palmert, M.R. (2005):** Regulation and disorders of pubertal timing. *Endocrinol. Metab. Clin. North. Am.*, 34:617–641.
- 219- **Nelson, S.M.; Yates, R.W.; Fleming, R. (2007):** Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles implications for individualization of therapy. *Hum. Reprod.*, 22:2414–2421.
- 220- **Nelson, S.M.; Yates, R.W.; Lyall, H.; Jamieson, M.; Traynor, I.; Gaudoin, M.; Mitchell, P.; Ambrose, P. and Richard Fleming, R. (2009):** Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. *Hum. Reprod.*, 24(4):867–875.
- 221- **Nielsen, C.T.; Richardson, D.W. and Hunter, W.M. et al. (1986):** Onset of the release of spermatozoa (spermarche) in boys in relation to age, testicular growth, pubic hair, and height. *J. Clin. Endocrinol. Metab.*, 62(3): 532–535.
- 222- **Nilsson, E.E. and Skinner, M.K. (2003):** Bone morphogenetic protein-4 acts as an ovarian follicle survival factor and promotes primordial follicle development. *Biol. Reprod.*, 69:1265–1272.
- 223- **Oestreich, A.E. (1997):** Tanner-Whitehouse versus Greulich-Pyle in bone age determinations. (editorial) *J. Pediatr.*, 131:5-6.
-

- 224- **Ohtsuki, F.; Mukherjee, D.; Lewis, A.B.; Roch, A.F. (1982):** Growth of the cranial base and vault dimensions in children. *American Journal of Physical Anthropology* 58:271-279.
- 225- **Orvis, G.D.; Jamin, S.P.; Kwan, K.M.; Mishina, Y.; Kaartinen, V.M.; Huang, S.; Roberts, A.B.; Umans, L.; Huylebroeck, D.; Zwijsen, A.; Wang, D.; Martin, J.F. and Behringer, R.R. (2008):** Functional Redundancy of TGF-beta Family Type I Receptors and Receptor-Smads in Mediating Anti-Müllerian Hormone-Induced Müllerian Duct Regression in the Mouse. *Biology of reproduction*, 78: 994–1001.
- 226- **Palmert, M.R. and Boepple, P.A. (2001):** Variation in the timing of puberty: Clinical spectrum and genetic investigation. *J. Clin. Endocrinol. Metab.*, 86:2364–2368.
- 227- **Papadimitriou, A. (2001):** Sex differences in the secular changes in pubertal maturation. *Pediatrics*, 108:65.
- 228- **Papadimitriou, A.; Wacharasindhu, S.; Pearl, K.; Preece, M.A. and Stanhope, R. (1991):** Treatment of constitutional growth delay in prepubertal boys with a prolonged course of low-dose oxandrolone. *Arch. Dis. Child*, 66: 841–843.
- 229- **Parry, R. L.; Chin, T.; Epstein, J.; Hudson, P. L.; Powell, D. M. and Donahoe, P. K. (1992):** *Cancer Res.*, 52:1182-1186.
- 230- **Partsch, C.J.; Hermanussen, M. and Sippell, W.G. (1985):** Differentiation of male hypogonadotropic hypogonadism and constitutional delay of puberty by pulsatile administration of gonadotropin-releasing hormone. *J. Clin. Endocrinol. Metab.*, 60:1196–1203.
- 231- **Pautier, P.; Lhomme, C.; Culine, S.; Duvillard, P.; Michel, G.; Bidart, J. M.; Gerbaulet, A. and Droz, J. P. (1997):** Adult granulosa-cell tumor of the ovary: a retrospective study of 45 cases. *Int. J. Gynecol. Cancer*, 7:58–65.
- 232- **Pellatt, L.; Hanna, L.; Brincat, M.; Galea, R.; Brain, H.; Whitehead, S. and Mason, H. (2007):** Granulosa cell production
-

- of anti-Müllerian hormone is increased in polycystic ovaries. *J. Clin. Endocrinol. Metab.*, 92:240–245.
- 233- Pellatt, L.; Rice, S. and Mason, H. (2010):** Anti-Müllerian hormone and polycystic ovary syndrome: A mountain too high?. *Reproduction* 139: 825-833.
- 234- Penarrubia, J.; Fabregues, F.; Manua, D.; Creus, M.; Casals, G.; Casamitja, R.; Carmona, F.; Vanrell, J.A. and Balasch, J. (2005):** Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response in as assisted reproductive technology cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotropin treatment. *Hum. Reprod.*, 20:915–922.
- 235- Pepinsky, R.B.; Sinclair, L.K.; Chow, E.P.; Mattaliano, R.J.; Manganaro, T.F.; Donahoe, P.K. et al. (1988):** Proteolytic processing of Müllerian inhibiting substance produces a transforming growth factor- β -like fragment. *J. Biol. Chem.*, 263:18961-18965.
- 236- Petersen, C. and Söder, O. (2006):** The Sertoli cell: a hormonal target and ‘super’ nurse for germ cells that determines testicular size. *Horm. Res.*, 66:153–161.
- 237- Picard, J.Y.; Benarous, R.; Guerrier, D.; Josso, N. and Kahn, A. (1986):** Cloning and expression of cDNA for anti-Müllerian hormone. *Proc. Natl. Acad. Sci. USA.*, 83:5464-5468.
- 238- Picard, J.Y.; Tran, D. and Josso, N. (1978):** Biosynthesis of labelled anti-Müllerian hormone by fetal testes: evidence for the glycoprotein nature of the hormone and for its disulfidebonded structure. *Mol. Cell Endocrinol.*; 12:17-30.
- 239- Picon, R. (1969):** Action of the fetal testis on the development in vitro of the Müllerian ducts in the rat. *Arch. Anat. Microsc. Morphol. Exp.*, 58:1-19.
- 240- Pieretti-Vanmarcke, R.; Donahoe, P.K.; Pearsall, L.A.; Dinulescu, D.M.; Connolly, D.C.; Halpern, E.F.; Seiden, M.V. and MacLaughlin, D.T. (2006):** Müllerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit

- human and mouse ovarian cancer. *Proc. Natl. Acad. Sci. USA*, 103:17426–17431.
- 241- Pigny, P.; Jonard, S.; Robert, Y. and Dewailly, D. (2006):** Serum anti-Müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.*, 91:941–945.
- 242- Piltonen, T.; Morin-Papunen, L.; Koinvunen, R.; Perheentupa, A.; Ruukonen, A. and Tapanainen, J.S. (2005):** Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in patients with polycystic ovary syndrome. *Hum. Reprod.*, 20:1820–1826.
- 243- Pirinen, S. (1995):** Endocrine regulation of craniofacial growth. *Acta. odontologica Scandinavica*, 53:179-185.
- 244- Pirinen, S.; Majurin, A.; Lenko, H.L. and Koski, K. (1994):** Craniofacial features in lake and excess of growth hormone. *Journal of Craniofacial Genetics and Developmental Biology*, 2:144-152.
- 245- Poyrazoğlu, S.; Günöz, H.; Darendeliler, F.; Saka, N.; Bundak, R. and Baş, F. (2005):** Constitutional delay of growth and puberty: from presentation to final height. *J. Pediatr. Endocrinol. Metab.*, 18(2):171-9.
- 246- Prader, A. (1975):** Delayed adolescence. *Clinics in Endocrinology and Metabolism*, 4:143-155.
- 247- Racine, C.; Rey, R.; Forest, M.G.; Louis, F.; Fere, A.; Huhtaniemi, I.; Josso, N.; Clemente, N. (1998):** Receptors for anti-Müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. *Proc. Natl. Acad. Sci.*, 95:594–599.
- 248- Raivio, T.; Falardeau, J.; Dwyer, A.; Quinton, R.; Hayes, F.J.; Hughes, V.A.; Cole, L.W.; Pearce, S.H.; Lee, H.; Boepple, P.; Crowley, W.F. and Pitteloud, N. (2007):** Reversal of idiopathic hypogonadotropic hypogonadism. *N. Engl. J. Med.* 357:863–873.
-

- 249- **Ranly, D.M. (ed.) (1998):** Somatic and craniofacial growth pattern correlations. In: A synopsis of craniofacial growth. Appleton and Lange, Norwalk, Connecticut, pp.185-208.
- 250- **Renaud, E.J.; MacLaughlin, D.T.; Oliva, E.; Rueda, B.R. and Donahoe, P.K. (2005):** Endometrial cancer is a receptor-mediated target for Müllerian Inhibiting Substance. *Proc. Natl. Acad. Sci. USA.*, 102:111–116.
- 251- **Rey, R. (2005):** Anti-Müllerian Hormone in Disorders of Sex Determination and Differentiation. *Arq. Bras. Endocrinol. Metab.*, 49:26-36.
- 252- **Rey, R.A.; Belville, C.; Nihoul-Fékété, C.; Michel-Calemard, L.; Forest, M.G.; Lahlou, N.; Jaubert, F.; Mowszowicz, I.; David, M.; Saka, N.; Bouvattier, C.; Bertrand, A.M.; Lecointre, C.; Soskin, S.; Cabrol, S.; Crosnier, H.; Léger, J.; Lortat-Jacob, S.; Nicolino, M.; Rabl, W.; Toledo, S.P.; Bas, F.; Gompel, A.; Czernichow, P. and Josso, N. (1999):** Evaluation of gonadal function in 107 intersex patients by means of serum anti-Müllerian hormone measurement. *J. Clin. Endocrinol. Metab.*, 84:627–631.
- 253- **Rey, R.A.; Codner, E.; Iñíguez, G.; Bedecarrás, P.; Trigo, R.; Okuma, C.; Gottlieb, S.; Bergadá, I.; Campo, S.M. and Cassorla, F.G. (2005):** Low risk of impaired testicular Sertoli and Leydig cell functions in boys with isolated hypospadias. *J. Clin. Endocrinol. Metab.*, 90:6035–6040.
- 254- **Rey, R.; Lordereau-Richard, I.; Carel, J.C.; Barbet, P.; Cate, R.L.; Roger, M.; Chaussain, J.L. and Josso, N. (1993):** Anti-Müllerian hormone and testosterone serum levels are inversely related during normal and precocious pubertal development. *J. Clin. Endocrinol. Metab.*, 77:1220–1226.
- 255- **Rey, R.; Lukas-Croisier, C.; Lasala, C. and Bedecarra's, P. (2003):** AMH/MIS: what we know already about the gene, the protein and its regulation. *Mol. Cell Endocrinol.*, 211:21–31.
- 256- **Rey, R.; Sabourin, J. C.; Venara, M.; Long, W. Q.; Jaubert, F.; Zeller, W. P.; Duvillard, P.; Chemes, H. and Bidart, J. M. (2000):** Anti-Müllerian hormone is a specific marker of Sertoli- and granulosa-cell origin in gonadal tumors. *Hum. Pathol.*, 31: 1202–1208.
-

- 257- **Ricquier, D. (2005):** Respiration uncoupling and metabolism in the control of energy expenditure. *Proc. Nutr. Soc.*, 64:47–52.
- 258- **Roberts, W.M.; Li, S.H.; Comite, F.; Hench, K.D.; Pescovitz, O.H.; Cutler, G.B. and Loriaux, D.L. (1985):** Dental development in precocious puberty. *Journal of Dental Research*, 64:1084-1086.
- 259- **Robertson, D.M.; Hale, G.E.; Fraser, I.S.; Hughes, C.L.; Burger, H.G. (2008):** A proposed classification system for menstrual cycles in the menopause transition based on changes in serum hormone profiles. *Menopause*, 15:1139–1144.
- 260- **Robertson, D.M.; Hale, G, E.; Jolley, D.; Fraser, I.S.; Hughes, C.L. and Burger, H.G. (2009):** Interrelationships between Ovarian and Pituitary Hormones in Ovulatory Menstrual Cycles across Reproductive Age. *J. Clin. Endocrinol. Metab.*, 94(1):138–144.
- 261- **Rockett, J.C.; Lynch, C.D.; and Germaine M. Buck, G.M. (2004):** Biomarkers for Assessing Reproductive Development and Health: Part 1- Pubertal Development. *Environ. Health Perspect.*, 112:105-112.
- 262- **Rodina, A.V.; Gukasova, N.V.; Makarov, V.A.; Kondrasheva, I. G.; Khomyakova, A.V.; Posypanova, G.A.; Popova, O.N.; Moskaleva, E. Y. and Severin, S.E. (2008):** Localization of Müllerian inhibiting substance receptors in various human cancer cell lines. *Biochemistry*, 73(7): 797-805.
- 263- **Roemmich, J.N.; Clark, P.A. and Mai, V. et al. (1998):** Alterations in growth and body composition during puberty: III. Influence of maturation, gender, body composition, fat distribution, aerobic fitness, and energy expenditure on nocturnal growth hormone release. *J. Clin. Endocrinol. Metab.*, 83(5):1440–1447.
- 264- **Rogol, A.D. (2005):** Pubertal androgen therapy in boys. *Pediatr. Endocrinol.*, 2(3):383-390.
- 265- **Rogol, A.D.; Clark, P.A. and Roemmich, J.N. (2000):** Growth and pubertal development in children and adolescents: effects of diet and physical activity. *Am. J. Clin. Nutr.*, 72:521–528.
-

- 266- Rosenbaum, M. and Leibel, R.L. (1998):** Leptin: a molecule integrating somatic energy stores, energy expenditure, and fertility. *Trends in Endocrinology and Metabolism*, 9:117–124.
- 267- Ruf, S. and Pancherz, H. (1996):** Development of the frontal sinus in relation to somatic and skeletal maturity. A cephalometric roentgenographic study at puberty. *European Journal of Orthodontics* 18: 491-497.
- 268- Salehpour, S.; Alipour, P.; Azar, M.R.; Laleh Ardeshtirpour, L.; Shamshiri, A.; Monfared, M.F. and Gharib, A. (2010):** A Double-Blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. *Horm. Res. Paediatr.*, 74:428–435.
- 269- Salhi, I.; Cambon-Roques, S.; Lamarre, I.; Laune, D.; Molina, F.; Pugni`Ere, M.; Pourquier, D.; Gutowski, M.; Picard, J.; Xavier, F. and Navarro-Teulon, I. (2004):** The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. *Biochem. J.*, 379: 785–793.
- 270- Schoenau, E. (1996):** A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. *J. Clin. Endocrinol. Metab.*, 81:3812–3813.
- 271- Schwindt, B.; Doyle, L.W. and Hutson, J.M. (1997):** Serum levels of Mullerian inhibiting substance in preterm and term male neonates. *J. Urol.*, 158:610–612.
- 272- Scully, R.E. (1995):** Pathology of ovarian cancer precursors. *Journal of Cellular Biochemistry Supplement*, 23:208–218.
- 273- Scully, R. E.; Young, R. H. and Clement, P. B. (1998):** Sex chord-stromal tumors, granulosa tumors. In *Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament* (Rosai, J., ed.), pp. 169–188, Armed Forces Institute of Pathology (AFIP), Washington.

- 274- Seckel, H.P. (1950):** Six examples of precocious sexual development. II . Studies in growth and maturation. American Journal of Diseases of Children, 79:278-309.
- 275- Sedlmeyer, I.L.; Hirschhorn, J.N. and Palmert, M.R. (2002):** Pedigree analysis of constitutional delay of growth and maturation: determination of familial aggregation and inheritance patterns. J. Clin. Endocrinol. Metab., 87:5581-5586.
- 276- Sedlmeyer, I.L. and Palmert, M.R. (2002):** Delayed puberty: analysis of a large case series from an academic center. J. Clin. Endocrinol. Metab., 87:1613-1620.
- 277- Sedlmeyer, I.L.; Pearce, C.L.; Trueman, J.A, Butler, J.L.; Bersaglieri, T.; Read, A.P.; Clayton, P.E.; Kolonel, L.N.; Henderson, B.E.; Hirschhorn, J.N. and Palmert MR. (2005):** Determination of sequence variation and haplotype structure for the gonadotropin-releasing hormone (GnRH) and GnRH receptor genes: investigation of role in pubertal timing. J. Clin. Endocrinol. Metab., 90:1091–1099.
- 278- Segal, T.Y.; Mehta, A.; Anazodo, A.; Hindmarsh, P.C. and Dattani, M.T. (2009):** Role of gonadotrophin-releasing hormone and human chorionic gonadotrophin stimulation tests in differentiating patients with Hypogonadism from those with constitutional delay of growth and puberty. J. Clin. Endocrinol. Metab., 94(3):780-785.
- 279- Segev, D.L.; Ha, T.U.; Tran, T.T.; Kenneally, M.; Harkin, P.; Jung, M.; MacLaughlin, D.T.; Donahoe, P.K. and Maheswaran, S. (2000):** Müllerian inhibiting substance inhibits breast cancer cell growth through an NF κ B -mediated pathway. J. Biol. Chem. 275:28371–28379.
- 280- Segev, D. L.; Hoshiya, Y.; Hoshiya, M.; Tran, T. T.; Carey, J. L.; Stephen, A. E.; MacLaughlin, D. T.; Donahoe, P. K. and Maheswaran, S. (2002):** Müllerian-inhibiting substance regulates NF- κ B signaling in the prostate in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A., 99: 239–244.
-

- 281- Seifer, D.B.; MacLaughlin, D.T.; Christian, B.P.; Feng, B. and Shelden, R.M. (2002):** Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. *Fertil. Steril.*, 77: 468 – 471.
- 282- Sempere, M.T. (2005):** Ghrelin: novel regulator of gonadal function. *J. Endocrinol. Invest.*, 28:26-29.
- 283- Sharpe, R.M.; McKinnell, C.; Kivlin, C. and Fisher, J.S. (2003):** Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. *Reproduction*, 125:769–784.
- 284- Shimasaki, S.; Moore, R.K.; Otsuka, F. and Erickson, G.F. (2004):** The bone morphogenetic protein system in mammalian reproduction. *Endocr. Rev.*, 25:72–101.
- 285- Silberstein, T.; MacLaughlin, D.T.; Shai, I.; Trimarchi, J.R.; Lambert-Messerlian, G.; Seifer, D.B.; Keefe, D.L. and Blazar, A.S. (2006):** Müllerian inhibiting substance levels at the time of HCG administrations in IVF cycles predict both the ovarian reserve and embryo morphology. *Hum. Reprod.*, 21:159–163.
- 286- Sinisi, A.A.; Esposito, D.; Maione, L.; Quinto, M.C.; Visconti, D.; A. De Bellis, A.; Bellastella, A.; Conzo, G. and Bellastella, G. (2008):** Seminal anti-Müllerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. *Human Reproduction*, 23: 1029–1034.
- 287- Sir-Petermann, T.; Codner, E.; Maliqueo, M.; Echiburu, B.; Hitschfeld, C.; Crisosto, N.; Perez-Bravo, F.; Recabarren, S.E. and Cassoria, F. (2006):** Increased anti-Müllerian hormone serum concentrations in the prepubertal daughters of women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.*, 91:3105–3109.
- 288- Siuda, E. k.; Tendra, E, M. and Siuda, K.K. (2006):** Influence of different parameters on final height of boys with constitutional

- delay of growth and puberty. *Endokrynol. Diabetol. Chor. Przemiany Materii. Wieku. Rozw.*, 12(3):159-62.
- 289- Skakkebaek, N.E.; Rajpert-De Meyts, E. and Main, K.M. (2001):** Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects: opinion. *Hum. Reprod.*, 16:972–978.
- 290- Sklar, C.A.; Kaplan, S.L. and Grumbach, M.M. (1980):** Evidence for dissociation between adrenarche and gonadarche: studies in patients with idiopathic precocious puberty, gonadal dysgenesis, isolated gonadotropin deficiency, and constitutionally delayed growth and adolescence. *J. Clin. Endocrinol. Metab.*, 51(3):548–556.
- 291- Smith, E.P.; Boyd, J.; Frank, G.R.; Takahashi, H.; Cohen, R.M.; Specker, B.; Williams, T.C.; Lubahn, D.B. and Korach, K.S. (1994):** Estrogens resistance caused by a mutation in the estrogen-receptor gene in a man. *New England Journal of Medicine* 331:1056-1061.
- 292- Soules, M.R.; Sherman, S.; Parrott, E.; Rebar, R.; Santoro, N.; Utian, W. and Woods, N. (2001):** Executive summary: stages of reproductive aging workshop (STRAW). *Fertil. Steril.*, 76:874–878.
- 293- Sowers, M.R.; Eyvazzadeh, A.D.; McConnell, D.; Yosef, M.; Jannausch, M.L.; Zhang, D.; Harlow, S. and Randolph J.J. (2008):** Anti-Müllerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. *J. Clin. Endocrinol. Metab.*, 93:3478–3483.
- 294- Spiegel, R.; Sather, H. and Hayles, A. (1971):** Cephalometric study of children with various endocrine diseases. *American Journal of Orthodontics* 59:362-375.
- 295- Sproul, K.; Jones, M.R.; Mathur, R.; Azziz, R. and Goodarzi, M.O. (2010):** Association study of four key folliculogenesis genes in polycystic ovary syndrome. *BJOG* 117: 756-760, 2010.
- 296- Stattin, H. (1990):** Pubertal maturation in female development. Hillsdale New Jersey: Erlbaum.
-

- 297- **Steel, G.H. (1965):** The relation between dental maturation and physiological maturity. *Dental Practitioner*, 16:23-34.
- 298- **Stephen, A.E.; Masiakos, P.T.; Segev, D.L.; Vacanti, J.P.; Donahoe, P.K. and MacLaughlin, D.T. (2001):** Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo. *Proceedings National Academy of Sciences USA*, 98:3214–3219.
- 299- **Stephen, A. E.; Pearsall, L. A.; Christian, B. P.; Donahoe, P. K.; Vacanti, J. P. and MacLaughlin, D. T. (2002):** Highly purified Müllerian inhibiting substance inhibits human ovarian cancer in vivo. *Clin. Cancer Res.*, 8: 2640–2646.
- 300- **Strobel, A.; Issad, T.; Camoin, L.; Ozata, M. and Strosberg, A.D. (1998):** A leptin missense mutation associated with hypogonadism and morbid obesity. *Nature Genetics*, 18:213–215.
- 301- **Styne, D. (1991):** Puberty and its disorders in boys. *Endocrinology and Metabolism clinics of North America*, 20:43-69.
- 302- **Sutherland, R.S.; Kogan, B.A. and Baskin, L.S. et al. (1996):** The effect of prepubertal androgen exposure on adult penile length. *J. Urol.*; 156:783–787.
- 303- **Taketo, T.; Saeed, J.; Manganaro, T.; Takahashi, M. and Donahoe, P.K. (1993):** Müllerian inhibiting substance production associated with loss of oocytes and testicular differentiation in the transplanted mouse XX gonadal primordium. *Biology of Reproduction*, 49:13–23.
- 304- **Tan, K.A.; De Gendt, K.; Atanassova, N.; Walker, M.; Sharpe, R.M.; Saunders, P.T.; Denolet, E. and Verhoeven, G. (2005):** The role of androgens in Sertoli cell proliferation and functional maturation: studies in mice with total or Sertoli cell-selective ablation of the androgen receptor. *Endocrinology*, 146:2674–2683.
- 305- **Tanner, J.M. (1962):** *Growth at Adolescence*. Springfield, IL: Charles C Thomas.
- 306- **Tanner, J. M. (1969):** Growth and endocrinology in the adolescent. In *Endocrine and Genetic Diseases of Childhood*. Ed. L. Gardner. Saunders, Philadelphia.
-

- 307- **Tanner, J.M. (ed.) (1978):** Physical growth from conception to maturity: In: Foetus into man. Open Books, London, pp.60-77.
- 308- **Tanner, J.M.; Whitehouse, R.H.; Cameron, N.; Marshall, W.A.; Healy, M.J. and Goldstein, H. (1983):** Assessment of skeletal maturity and prediction of adult height, 2nd ed. London: Academic Press.
- 309- **Tanner, J.M.; Whitehouse, R.H.; Marubini, E. and Resele, L.F. (1976):** The adolescent growth spurt of boys and girls of the Harpenden growth study. *Ann. Hum. Biol.*, 3:109–126.
- 310- **Tapanainen, J.S.; Aittomaki, K.; Min, J.; Vaskivuo, T. and Huhtaniemi, I.T. (1997):** Men homozygous for an inactivating mutation of the follicle-stimulating hormone receptor gene present variable suppression of spermatogenesis and fertility. *Nat. Genet.*, 15:205–206.
- 311- **Tarlatzis, B.C.; Zepiridis, L.; Grimbizis, G. and Bontis, J. (2003):** Clinical management of low ovarian response to stimulation for IVF: a systematic review. *Hum. Reprod. Update*; 9:61–76.
- 312- **Tehrani, F.R.; Solaymani-Dodaran, M. and Azizi F. (2009):** A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. *Menopause*, 16(4):797-802.
- 313- **Teixeira, J. and Donahoe, P. K. (1996):** Molecular biology of MIS and its receptors. *J. Androl.*, 17: 336–341.
- 314- **Teixeira, J.; Kehas, D. J.; Antun, R. and Donahoe, P. K. (1999):** Transcriptional regulation of the rat Müllerian inhibiting substance type II receptor in rodent Leydig cells. *Proc. Natl. Acad. Sci. U.S.A.*, 96: 13831–13838.
- 315- **Teixeira, J.; Maheswaran, S. and Donahoe, P. K. (2001):** Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. *Endocr. Rev.*, 22: 657–674.
- 316- **Toulis, K.A.; Iliadou, P.K.; Venetis, C.A.; Tsametis, C.; Tarlatzis, B.C.; Papadimas, I. and Goulis, D.G. (2010):** Inhibin B and anti-Müllerian hormone as markers of persistent
-

- spermatogenesis in men with non-obstructive azoospermia: a meta-analysis of diagnostic accuracy studies. *Hum. Reprod. Update.*, 16(6):713-724.
- 317- Tuttelmann, F.; Dykstra, N.; Med.,C.; Themmen, A.P.; Jenny A. Visser, J.A.; Eberhard Nieschlag, E. and Manuela Simoni, M. (2009):** Anti-Müllerian hormone in men with normal and reduced sperm concentration and men with maldescended testes. *Fertil. Steril.*, 91(5):1812-9.
- 318- Uruena, M.; Pantisiotou, S.; Preece, M.A. and Stanhope, R. (1992):** Is testosterone therapy for boys with constitutional delay of growth and puberty associated with impaired final height and suppression of the hypothalamo-pituitary-gonadal axis? *European Journal of Pediatrics*, 151:15-18.
- 319- van Disseldorp, J.; Faddy, M.J.; Themmen, A.P.; de Jong, F.H.; Peeters, P.H.; van der Schouw, Y.T. and Broekmans, F.J. (2008):** Relationship of serum anti-Müllerian hormone concentration to age at menopause. *J. Clin. Endocrinol. Metab.*, 93: 2129–2134.
- 320- van Erum, R.; Mulier, G., Carels, C.; Verbeke, G. and de Zegher, F. (1997):** Craniofacial growth in short children born small for gestational age: effect of growth hormone treatment. *J. Dent. Res.*, 76(9):1579-86.
- 321- van Rooij, I.A.; Broekmans, F.J.; Scheffer, G.J.; Looman, C.W.; Habbema, J.D.; de Jong, F.H.; Fauser, B.J.; Themmen, A.P. and te Velde, E.R. (2005):** Serum anti-Müllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. *Fertil. Steril.*, 83:979–987.
- 322- van Rooij, I.A.; Broekmans, F.J.; Velde, E.; Fauser, B.C.; Bansci, L.F.; de Jong, F.H. and Themmen, A.P. (2002):** Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. *Hum. Reprod.*, 17:3065–3071.
- 323- Veldhuis, J.D.; Roemmich, J.N. and Rogol, A.D. (2000):** Gender and sexual maturation-dependent contrasts in the neuroregulation of
-

- growth hormone secretion in prepubertal and late adolescent males and females-a general clinical research center-based study. *J. Clin. Endocrinol. Metab.*, 85(7):2385–2394.
- 324- Verdonck, A.; Gaethofs, M.; Carels, C. and de Zegher, M. (1999):** Effect of low-dose testosterone treatment on craniofacial growth in boys with delayed puberty. *European Journal of Orthodontics*, 21:137-143.
- 325- Verma, D.; Peltomäki, T. and Jäger, A. (2009):** Reliability of growth prediction with hand-wrist radiographs. *European Journal of Orthodontics* 31: 438–442.
- 326- Visser, J. A. (2003):** AMH signaling: from receptor to target gene. *Mol. Cell Endocrinol.*, 211: 65-73.
- 327- Visser, J.A.; de Jong, F.H.; Laven, J.S. and Themmen, A.P. (2006):** Anti-Müllerian hormone: a new marker for ovarian function. *Reproduction*, 131:1–9.
- 328- Visser, J.A. and Themmen, P.N. (2005):** Anti-Müllerian hormone and folliculogenesis. *Mol. Cell. Endocrinol.*, 234:81–86.
- 329- Visser, J. A.; Olaso, R.; Verhoef-Post, M.; Kramer, P.; Themmen, A. P. and Ingraham, H. A. (2001):** The serine/threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling. *Mol. Endocrinol.*, 15: 936–945.
- 330- Vogl, T.J.; Stemmler, J.; Heye, B.; Schopohl, J.; Danek, A. and Bergman, C. et al. (1994):** Kallman syndrome versus idiopathic hypogonadotropic hypogonadism at MR imaging. *Radiology*, 191:53–57.
- 331- Waal, H.A.; Wennink, J.M. and Odink, R.J. (1991):** Gonadotrophin and growth hormone secretion throughout puberty. *Acta. Pediatr. Scand. Suppl.*, 372:26–31.
- 332- Wang, P.Y.; Koishi, K.; McGeachie, A.B.; Kimber, M.; MacLaughlin, D.T.; Donahoe, P.K. and McLennan, I.S. (2005):** Müllerian inhibiting substance acts as a motor neuron survival factor in vitro. *Proc. Natl. Acad. Sci. USA*, 102:16421–16425.
-

- 333- Wang, P.Y.; Protheroe, A.; Clarkson, A.N.; Imhoff, F.; Koishi, K. and McLennan, I.S. (2009):** Müllerian inhibiting substance contributes to sex-linked biases in the brain and behavior. *Proc. Natl. Acad. Sci. USA*, 106(17): 7203-7208.
- 334- Watanabe, K.; Clarke, T.R.; Lane, A.H.; Wang, X. and Donahoe, P.K. (2000):** Endogenous expression of Müllerian inhibiting substance in early postnatal rat Sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites. *Proc. Natl. Acad. Sci. USA*, 97:1624-1629.
- 335- Weenen, C.; Laven, J.S.; Von Bergh, A.R.; Cranfield, M.; Groome, N.P.; Visser, J.A.; Kramer, P.; Fauser, B.C. and Themmen, A.P. (2004):** Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. *Mol. Hum. Reprod.*, 10:77–83.
- 336- Wehkalampi, K.; Wide´ n, E.; Laine, T.; Palotie, A.; and Dunkel, L. (2008):** Patterns of Inheritance of Constitutional Delay of Growth and Puberty in Families of Adolescent Girls and Boys Referred to Specialist Pediatric Care. *J. Clin. Endocrinol. Metab.*, 93: 723–728.
- 337- Weiss, J.; Axelrod, L.; Whitcomb, R.W.; Harris, P.E.; Crowley, W.F. and Jameson, J.L. (1992):** Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. *N. Engl. J. Med.*, 326:179–183.
- 338- Weiss, J.; Crowley, W.F. and Jameson, J.L. (1989):** Normal structure of the gonadotropin-releasing hormone (GnRH) gene in patients with GnRH deficiency and idiopathic hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.*, 69:299–303.
- 339- Whatmore, A. J.; Hall, C. M.; Jones, J.; Westwood, M. and Clayton, P.E. (2003):** Ghrelin concentrations in healthy children and adolescents. *Clinical Endocrinology*, 59: 649-654.
- 340- Wikland, K.; Rosberg, S. and Lannering, B. et al. (1997):** Twenty-four-hour profiles of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol levels: a semi-longitudinal study throughout puberty in healthy boys. *J. Clin. Endocrinol. Metab.*, 82(2):541–549.
-

- 341- Wikström, A.M.; Hoei-Hansen, C.E.; Leo Dunkel, L. and Meyts, E.R. (2007):** Immunoexpression of Androgen Receptor and Nine Markers of Maturation in the Testes of Adolescent Boys with Klinefelter Syndrome: Evidence for Degeneration of Germ Cells at the Onset of Meiosis. *J. Clin. Endocrinol. Metab.*, 92: 714–719.
- 342- Wilhelm, D.; Palmer, S.; and Koopman, P. (2007):** Sex determination and gonadal development in mammals. *Physiol. Rev.*, 87:1–28.
- 343- Wolfe, R.R. (1992):** Radioactive and stable isotope tracers in biomedicine. New York: Wiley-Liss Inc.; 207–233.
- 344- Wren, R.E.; Blume, H.; Mazariegos, M.; Solomons, N.; Alvarez, J.O. and Goran, M.I. (1997):** Body composition, resting metabolic rate, and energy requirements of short and normal-stature, low-income Guatemalan children. *Am. J. Clin. Nutr.*, 66:406–412.
- 345- Wudy, S.A.; Hagemann, S.; Dempfle, A.; Ringler, G.; Blum, W.F.; Berthold, L.D.; Alzen, G.; Gortner, L. and Hebebrand, J. (2005):** Children with idiopathic short stature are poor eaters and have decreased body mass index. *Pediatrics*, 116:52-57.
- 346- Wunder, D.M.; Bersinger, N.A.; Yared, M.; Kretschmer, R. and Birkhäuser, M.H. (2008):** Statistically significant changes of anti Müllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. *Fertil. Steril.*, 89:927–933.
- 347- Xavier, F. and Allard, S. (2003):** Anti-Müllerian hormone, [beta]-catenin and Müllerian duct regression. *Mol. Cell Endocrinol.* 211:115-121.
- 348- Young, J.; Chanson, P.; Salenave, S.; Noël, M.; Brailly, S.; O’Flaherty, M.; Schaison, G. and Rey, R. (2005):** Testicular anti-Müllerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.*, 90:724–728.
- 349- Zachmann, M.; Prader, A. and Kind, H.P. et al. (1974):** Testicular volume during adolescence: cross-sectional and longitudinal studies. *Helv. Pediatr. Acta.*, 29(1):61–72.
-

- 350- Zadik, Z.; Sinai, T.; Zung, A. and Reifen, R. (2004):** Vitamin A and iron supplementation is as efficient as hormonal therapy in constitutionally delayed children. *Clin. Endocrinol. (Oxf)*, 60: 682–687.
- 351- Zerlin, J.M. and Hernandez, R.J. (1991):** Approach to skeletal maturation. *Hand Clin.*, 7:53–62.